Emily D Cole1, Daniela Ferrara, Eduardo A Novais, Ricardo N Louzada, Nadia K Waheed. 1. *New England Eye Center, Tufts Medical Center, Boston, Massachusetts; †Department of Electrical Engineering and Computer Science, and Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, Massachusetts; ‡Federal University of Goiás, Goiânia, Brazil; and §School of Medicine, Federal University of São Paulo, São Paulo, Brazil.
Abstract
PURPOSE: To describe qualitative and quantitative optical coherence tomography (OCT) angiography (OCTA) parameters for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and their applicability as potential clinical trial endpoints. METHODS: A review of current literature related to the topic of OCTA and AMD. RESULTS: There are a number of promising OCTA parameters that can be used to diagnose the presence of CNV and to monitor the activity and progression of the lesion, pre- and post-treatment morphological characteristics, CNV dimensions, and automated quantitative parameters such as vessel density. CONCLUSION: The OCTA parameters described in this review have promise for the future development of clinical trial endpoints, but require further validation before they can be widely used.
PURPOSE: To describe qualitative and quantitative optical coherence tomography (OCT) angiography (OCTA) parameters for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and their applicability as potential clinical trial endpoints. METHODS: A review of current literature related to the topic of OCTA and AMD. RESULTS: There are a number of promising OCTA parameters that can be used to diagnose the presence of CNV and to monitor the activity and progression of the lesion, pre- and post-treatment morphological characteristics, CNV dimensions, and automated quantitative parameters such as vessel density. CONCLUSION: The OCTA parameters described in this review have promise for the future development of clinical trial endpoints, but require further validation before they can be widely used.
Authors: Ian C Holmen; Sri Meghana Konda; Jeong W Pak; Kyle W McDaniel; Barbara Blodi; Kimberly E Stepien; Amitha Domalpally Journal: JAMA Ophthalmol Date: 2020-02-01 Impact factor: 7.389
Authors: Carl B Rebhun; Eric M Moult; Stefan B Ploner; Carlos Moreira Neto; A Yasin Alibhai; Julia Schottenhamml; Byungkun Lee; WooJhon Choi; Fareed A Rifai; Mary W Tam; Lennart Husvogt; Caroline R Baumal; Andre J Witkin; Andreas Maier; Philip J Rosenfeld; Jay S Duker; James G Fujimoto; Nadia K Waheed Journal: Ophthalmol Retina Date: 2017-10-31
Authors: J L Lauermann; M Treder; P Heiduschka; C R Clemens; N Eter; F Alten Journal: Graefes Arch Clin Exp Ophthalmol Date: 2017-05-04 Impact factor: 3.117
Authors: J L Lauermann; A K Woetzel; M Treder; M Alnawaiseh; C R Clemens; N Eter; Florian Alten Journal: Graefes Arch Clin Exp Ophthalmol Date: 2018-07-07 Impact factor: 3.117
Authors: Marcus Ang; Anna C S Tan; Chui Ming Gemmy Cheung; Pearse A Keane; Rosa Dolz-Marco; Chelvin C A Sng; Leopold Schmetterer Journal: Graefes Arch Clin Exp Ophthalmol Date: 2018-01-09 Impact factor: 3.117
Authors: Fang Zheng; Qinqin Zhang; Elie H Motulsky; João Rafael de Oliveira Dias; Chieh-Li Chen; Zhongdi Chu; Andrew R Miller; William Feuer; Giovanni Gregori; Sophie Kubach; Mary K Durbin; Ruikang K Wang; Philip J Rosenfeld Journal: Invest Ophthalmol Vis Sci Date: 2017-10-01 Impact factor: 4.799